Long Non-coding RNAs and CRISPR-Cas Edition in Tumorigenesis

Adv Exp Med Biol. 2023:1429:41-58. doi: 10.1007/978-3-031-33325-5_3.

Abstract

Long non-coding RNAs (lncRNAs) are one of the most abundant and heterogeneous transcripts with key roles in chromatin remodeling and gene regulation at the transcriptional and post-transcriptional levels. Due to their role in cell growth and differentiation, lncRNAs have emerged as an important biomarker in cancer diagnosis, prognosis, and targeted treatment. Recent studies have focused on elucidating lncRNA function during malignant transformation, tumor progression and drug resistance. The advent of the CRISPR system has made it possible to precisely edit complex genomic loci such as lncRNAs. Thus, we summarized the advances in CRISPR-Cas approaches for functional studies of lncRNAs including gene knockout, knockdown, overexpression and RNA targeting in tumorigenesis and drug resistance. Additionally, we highlighted the perspectives and potential applications of CRISPR approaches to treat cancer, as an emerging and promising target therapy.

MeSH terms

  • CRISPR-Cas Systems / genetics
  • Cell Transformation, Neoplastic / genetics
  • Gene Expression Regulation
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding